Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To investigate whether microRNA-19a can promote the proliferative and migratory abilities of non-small cell lung cancer (NSCLC) cells by target inhibition of PTEN (phosphatase and tensin homolog deleted from chromosome 10, PTEN) expression, thus leading to the development of NSCLC.
|
31424647 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that miR-561 inhibits NSCLC cell proliferation and G1-S transition and induces apoptosis through suppression of the PTEN/AKT signaling pathway by targeting P-REX2a.
|
31711559 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Taken together, we proved that miR-224 might play essential roles in cellular functions of nutrient-depleted A549 cells possibly through regulating the target PTEN and downstream signal PI3K, suggesting the potential of miR-224 to be a therapeutic target for NSCLC therapy.
|
31190892 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We first found that higher TG2 expression level and lower PTEN and IκBα expression levels in the intrinsic EGFR-TKI resistant NSCLC compare with EGFR-TKI sensitive NSCLC.
|
31497352 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that LINC00702 modulated the expression of PTEN gene by acting as a ceRNA for miR-510 in NSCLC.
|
30840927 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, rescue experiments were conducted to assess the involvement of PTEN in the development of NSCLC.
|
31695021 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, LINC00342 promoted proliferation by inhibiting the expression of p53 and PTEN proteins in NSCLC cell lines.
|
30320899 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The results revealed that compared with normal control cells, PTEN levels were significantly decreased in NSCLC cell lines (P<0.01).
|
30655903 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
MAGI2-AS3 is downregulated in NSCLC.Overexpression of MAGI2-AS3 suppresses the proliferative and invasive abilities of NSCLC via miRNA-23a-3p/PTEN axis.
|
31539127 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Regulation of miR-4262 and PTEN expressions in NSCLC was conducted by transfection.
|
31337279 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The present findings suggested that treatment with pemetrexed may exhibit synergistic effects with PTEN on lung cancer cells via the inhibition of the PI3K/AKT/mTOR signaling pathway and through carbohydrate metabolism, and treatment with pemetrexed combined with PTEN overexpression may represent a novel therapeutic strategy for the treatment of NSCLC.
|
31485626 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have conducted this study to check the effect of VCN-2 on the cell viability and the effect on PTEN (Phosphatase and tensin homolog), PI3KCA (Phosphatidylinositol 4, 5-biphosphate 3-kinase catalytic subunit alpha isoform/PI3K 110α subunit), and Akt1 when VCN-2 was used alone and in combination with radiation in the NSCLC cell line NCI-H23 (H23).
|
30496626 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The expression of miR-21 in tumor cell lines and clinical NSCLC tumor samples was positively correlated with hypoxia-inducible factor-1α and negatively correlated with PTEN.
|
30881046 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Further, we demonstrated that SIRT3 promoted degradation of P53 in PTEN-deficient NSCLC cell lines via the ubiquitin-proteasome pathway.
|
29103158 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We firstly indicated that miR-4299 may be a candidate independent marker for NSCLC prognosis and suppressed the progression of NSCLC by modulating the activation of PTEN/AKT/PI3K signaling pathway, suggesting that miR-4299 could be a potential target for developing therapies in treating NSCLC.
|
29917192 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we showed that YM155 markedly enhanced the sensitivity of erlotinib to EGFR-TKI resistant NSCLC cell lines H1650 (EGFR exon 19 deletion and PTEN loss) and A549 (EGFR wild type and KRAS mutation) through inducing autophagy-dependent apoptosis and autophagic cell death.
|
30315932 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In order to further investigate the possible role of hsa_circ_0033155 in NSCLC progression, circRNA was overexpressed in NSCLC cells and it was observed that the overexpression of hsa_circ_0033155 significantly decreased cell proliferation, colony formation and migration, and elevated the level of phosphatase and tensin homolog deleted on chromosome 10, a tumor suppressor in many types of tumor.
|
30214545 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inversely, increased miR-374a was an unfavorable factor when targeting PTEN in more advanced staged NSCLC patients.
|
29362431 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In total 50 plasma samples from patients newly diagnosed with advanced NSCLC or resistant to first-line tyrosine kinase inhibitors (TKIs) were subjected to deep sequencing on a seven-gene panel (BRAF, EGFR, ERBB2, KRAS, NRAS, PIK3CA, PTEN) incorporated with molecular barcodes to improve accuracy in variant detection.
|
30268455 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Therefore, our study demonstrated that miR-142-5p regulated CD4+ T cells in human NSCLC through PD-L1 expression via the PTEN pathway.
|
29767245 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
qRT-PCR analysis was used to detect the expression of TP53TG1, miR-18a and PTEN mRNA in NSCLC tissues and cells.
|
29588850 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
miR-486-5p functions as an oncogene by targeting PTEN in non-small cell lung cancer.
|
29567332 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, upregulation of miR-584 was involved in the regulation of the phosphatase and tensin homolog/Akt serine/threonine kinase signalling pathway in NSCLC.
|
29434826 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Further, we showed that the LNA treatment rescues PTEN expression in non-small-cell lung cancer (NSCLC) cells, which is suppressed by the elevated level of miRNA 92b.
|
29529863 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To the best of our knowledge, this is the first case of NSCLC harboring concurrent PTEN and TP53 mutations with widespread and strong coexpression of TTF-1 and p40, which has been confirmed in the resected specimen, and only the second documented case of NSCLC with TTF-1 and p40 diffuse coexpression in the carcinoma cells from the same individual.
|
29410129 |
2018 |